Zyla Life Sciences Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Zyla Life Sciences inventory turnover ratio, the Zyla Life Sciences's ability to sell and replace its inventory in the first quarter 2020, sequentially increased to 1.47 in the first quarter 2020, a new company high. Average inventory processing period, for the Zyla Life Sciences in Mar 31 2020 quarter, has decreased to 248 days, compare to 397 days, in the Dec 31 2019 quarter.

Within Healthcare sector 314 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1849 in the fourth quarter 2019, to 1850.

EGLT Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Zyla Life Sciences Market Share?

What is Inventory Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Inventory Turnover▼

None ▼

Inventory Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

EGLT Inventory Turnover Ratio	(Mar 31 2020) I. Quarter	(Dec 31 2019) IV. Quarter	(Sep 30 2019) III. Quarter	(Jun 30 2019) II. Quarter	(Mar 31 2019) I. Quarter
Y / Y Inventory Growth	-55.83 %	242.9 %	213.85 %	358.22 %	1001.56 %
Y / Y Cost of Sales Growth	551.21 %	957.31 %	564.83 %	558.57 %	0 %
Inventory Turnover Ratio (TTM)	1.47	0.92	0.64	0.47	0.26
EGLT's Total Ranking	# 1850	# 1849	# 1854	# 1853	# 1853
Average inventory processing period	249	398	568	783	1392
Seq. Inventory Growth	13.61 %	-5.13 %	-34.6 %	-37.34 %	782 %
Seq. Cost of Sales Growth	-35.53 %	55.1 %	0 %	551.21 %	4.68 %

Inventory Turnover Ratio Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 101
Healthcare Sector	# 315
Overall Market	# 1850

Inventory Turnover Ratio Statistics
High	Average	Low
1.47	0.9	0.26
(Mar 31 2020)		(Mar 31 2019)

EGLT Company Profile >> Back to EGLT Efficiency Comparisons >> Compare EGLT Inventory Turnover Ratio to its Competitors

Financial Statements
Zyla Life Sciences's Inventories	$ 10 Millions	Visit EGLT's Balance sheet
Zyla Life Sciences's Cost of Revenues TTM	$ 16 Millions	Visit EGLT's Income Statement
What are EGLT's Sales?		Visit EGLT's Sales by Segment

Other Inventory Turnover Ratios
Zyla Life Sciences's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
EGLT's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for EGLT's Competitors
Inventory Turnover Ratio for EGLT's Suppliers
Inventory Turnover Ratio for EGLT's Customers

You may also want to know
EGLT's Sales Growth Rates	EGLT's Pe Price to earnings ratio	EGLT's Receivables Turnover Ratio	EGLT's Stock Quote
EGLT's Net Income Growth Rates	EGLT's Ps Price to Sales ratio	EGLT's Sales per Employee	EGLT's Asset Turnover Ratio
EGLT's Net Margin	EGLT's Pb Price to Book ratio	EGLT's Financial Strength Ratios	EGLT's Dividend Payout Ratio

Companies with similar Inventory Turnover Ratio for the quarter ending Mar 31 2020, within Healthcare Sector	Inventory Turnover Ratio	Cost of revenues at quarter ending Mar 31 2020	Inventories at quarter ending Mar 31 2020
Icu Medical Inc	4.23	$ 1,398.868 Millions	$ 331 Millions
Abbvie Inc	4.16	$ 7,772.000 Millions	$ 1,870 Millions
Mylan N v	4.14	$ 11,234.900 Millions	$ 2,713 Millions
Tandem Diabetes Care Inc	4.12	$ 183.116 Millions	$ 44 Millions
Bristol myers Squibb Company	4.11	$ 9,896.000 Millions	$ 2,407 Millions
Envista Holdings Corporation	4.09	$ 1,171.900 Millions	$ 287 Millions
3m Company	4.07	$ 16,935.000 Millions	$ 4,165 Millions
Msa Safety Inc	4.07	$ 773.099 Millions	$ 190 Millions
Mimedx Group Inc	4.03	$ 45.688 Millions	$ 11 Millions
American Cryostem Corporation	4.00	$ 0.116 Millions	$ 0 Millions
Baxter International Inc	3.92	$ 6,688.000 Millions	$ 1,705 Millions
Prophase Labs Inc	3.92	$ 6.936 Millions	$ 2 Millions
Neurometrix Inc	3.90	$ 5.323 Millions	$ 1 Millions
Novocure Limited	3.89	$ 93.288 Millions	$ 24 Millions
Bespoke Extracts Inc	3.87	$ 0.057 Millions	$ 0 Millions
Immucell Corporation	3.86	$ 8.968 Millions	$ 2 Millions
Amag Pharmaceuticals inc	3.80	$ 113.075 Millions	$ 30 Millions
Dynatronics Corporation	3.75	$ 42.575 Millions	$ 11 Millions
Integer Holdings Corporation	3.75	$ 678.135 Millions	$ 181 Millions
Vertex Pharmaceuticals Inc	3.73	$ 615.163 Millions	$ 165 Millions
Reliv International Inc	3.70	$ 9.778 Millions	$ 3 Millions
Sonoma Pharmaceuticals Inc	3.69	$ 10.603 Millions	$ 3 Millions
Bausch Health Companies Inc	3.62	$ 2,278.000 Millions	$ 630 Millions
Teva Pharmaceutical Industries Limited	3.60	$ 8,875.000 Millions	$ 2,464 Millions
Avadel Pharmaceuticals Plc	3.58	$ 11.316 Millions	$ 3 Millions
Kadmon holdings inc	3.57	$ 1.413 Millions	$ 0 Millions
Quidelortho Corp	3.56	$ 216.706 Millions	$ 61 Millions
Zeo Scientifix Inc	3.56	$ 0.384 Millions	$ 0 Millions
Luna Innovations Inc	3.53	$ 36.045 Millions	$ 10 Millions
Organogenesis Holdings Inc	3.52	$ 77.761 Millions	$ 22 Millions

Date modified: 2026-08-29T17:26:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.